Sosei Heptares (the corporate brand of Sosei Group Corporation) is a research-focused biotechnology group, publicly listed on the Tokyo Stock Exchange (TSE: 4565) and with sites in Tokyo, London and Cambridge (UK).
Our mission is to make a significant contribution to improving the quality of life and health of people around the world. To achieve this, we will discover, design and initiate development of the most innovative and effective medicines for patients worldwide, utilising our world-leading patent-protected technology and platform.
Our primary focus is the discovery, design and in selected cases early clinical development of new medicines originating from our proprietary G Protein-Coupled Receptor (GPCR) targeted StaR® technology and Structure Based Drug Design (SBDD) platform capabilities. We are advancing a broad and deep pipeline of in novel medicines across multiple therapeutic areas including neurology, immuno-oncology, gastroenterology and inflammation. Our leading clinical programs include partnered candidates aimed at the symptomatic treatment of Alzheimer’s disease (with Allergan) and next generation immuno-oncology approaches to treat cancer (with AstraZeneca). Our additional partners and collaborators include Takeda, Genentech, Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys.
Sosei Heptares has approximately 145 employees based at its new facility at Granta Park, Cambridge, UK. The size of the company ensures a transparent linkage between all activities from target to clinic.
We are currently looking to strengthen our Molecular Pharmacology team and are now seeking to recruit highly motivated laboratory-based in vitro pharmacologists to join our team. The Molecular Pharmacology team is responsible for both new drug target validation and supporting all drug discovery phases up to pre-clinical candidate (PCC) selection via performing assays to study pathological characteristics of GPCRs in disease.
This role will include tasks relating to assay development, provision of routine small/large molecule screening and more detailed mechanism of action studies in native cellular systems.
The successful candidate is expected to have:
An undergraduate/postgraduate degree in pharmacology or similar biological sciences or relevant industrial experience.
Practical laboratory experience (such as mammalian cell culture, experience in recombinant cell-based assays).
Strong numerical and analytical ability.
Excellent communication and interpersonal skills and demonstrated capability to operate in a collaborative and entrepreneurial environment.
The ability to communicate clearly, both verbally and in written reports, in English.
Desirable but not essential includes:
Prior experience in GPCRs
Practical neuroscience experience (such as experience in culturing primary neurones or iPSCs)
Previous experience using automation (such as automatic liquid handlers)
We offer a competitive salary, commensurate with qualifications and experience, and benefits package including pension and healthcare schemes.
The successful candidate will be employed by Heptares Therapeutics Ltd, a UK wholly owned subsidiary of Sosei Group Corporation.
Applications should include a covering letter, providing a short description of the background to their interest in the role, with curriculum vitae including the names and contact details for two referees. Please send your application in pdf format, quoting reference number 2019/5MP and apply via our on-line recruitment portal: https://soseiheptares.com/careers-2.html
The posting date is: 6th November 2019. The closing date for applications is 6th December 2019.
Strictly no agencies.